Does the Use of Immunosuppressive Drugs Impact on SARS-CoV-2 Infection Outcome? Data From A National Cohort of Patients With Immune-Mediated Inflammatory Diseases (SAR-COVID Registry)
| Autor: | Carolina Ayelen, Isnardi, Enrique R, Soriano, Cesar, Graf, María Celina, de la Vega, Bernardo A, Pons-Estel, Karen, Roberts, Rosana, Quintana, Gimena, Gomez, Jinoos, Yazdany, Verónica, Saurit, Roberto Miguel, Báez, Vanessa Viviana Castro, Coello, Cecilia Nora, Pisoni, Guillermo, Berbotto, Florencia, Vivero, Marcos David, Zelaya, María J, Haye Salinas, Álvaro A, Reyes Torres, Sofía, Ornella, Romina Estefanía, Nieto, Federico Nicolás, Maldonado, María Julieta, Gamba, María de Los Ángeles, Severina, Yohana, Tissera, Paula, Alba, Adriana Karina, Cogo, Gelsomina, Alle, Carla, Gobbi, Andrea, Baños, Edson, Velozo, Mariana, Pera, Romina, Tanten, Juan Alejandro, Albiero, Hernán, Maldonado Ficco, María Victoria, Martire, María Soledad Gálvez, Elkin, Micaela, Cosatti, María Alejandra, Cusa, Dora, Pereira, Verónica G, Savio, Guillermo J, Pons-Estel |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
SARS-CoV-2 Arthritis Inflammatory and immune system Clinical Sciences Argentina COVID-19 Autoimmune Disease Arthritis & Rheumatology Immunomodulating Agents Infectious Diseases Good Health and Well Being Rheumatology Clinical Research Rheumatoid rheumatic diseases Humans Registries Lung Immunosuppressive Agents |
| Zdroj: | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol 29, iss 2 |
| ISSN: | 1536-7355 1076-1608 |
| Popis: | Background/objectiveThis study describes the impact of immunomodulatory and/or immunosuppressive (IM/IS) drugs in the outcomes of COVID-19 infection in a cohort of patients with immune-mediated inflammatory diseases (IMIDs).MethodsAdult patients with IMIDs with a confirmed SARS-CoV-2 infection were included. Data were reported by the treating physician between August 13, 2020 and July 31, 2021. Sociodemographic data, comorbidities, and DMARDs, as well as clinical characteristics, complications, and treatment of the SARS-CoV-2 infection, were recorded. Descriptive analysis and multivariable logistic regression models were carried out.ResultsA total of 1672 patients with IMIDs were included, of whom 1402 were treated with IM/IS drugs. The most frequent diseases were rheumatoid arthritis (47.7%) and systemic lupus erythematosus (18.4%). COVID-19 symptoms were present in 95.2% of the patients. A total of 461 (27.6%) patients were hospitalized, 8.2% were admitted to the intensive care unit, and 4.4% died due to COVID-19.Patients without IM/IS treatment used glucocorticoids less frequently but at higher doses, had higher levels of disease activity, were significantly older, were more frequently hospitalized, admitted to the intensive care unit, and died due to COVID-19. After adjusting for these factors, treatment with IM/IS drugs was not associated with a worse COVID-19 outcome (World Health Organization-Ordinal Scale ≥5) (odds ratio, 1.24; 95% confidence interval, 0.73-2.06).ConclusionsSAR-COVID is the first multicenter Argentine registry collecting data from patients with rheumatic diseases and SARS-CoV-2 infection. After adjusting for relevant covariates, treatment with IM/IS drugs was not associated with severe COVID-19 in patients with IMIDs.Study registrationThis study has been registered in ClinicalTrials.gov under the number NCT04568421. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|